South Alabama Medical Science Foundation
Cash Receipts (For Projects Over $2,000)
October 1, 2023 - September 30, 2024

Department	Project Number	Project Title	Principal Investigator	Source of Funding	23-24 Receipts
Internal Medicine					
	63891	CorEvitas Inflammatory Bowel Disease (IBD) Drug Safety and Effectiveness Registry (Corrona IBD-600 Registry)	Dr Sonnier, W	CorEvitas	39,930.00
	63939	Protocol No. 19767: A multicenter, international, randomized, active comparator-controlled, double-blind, double dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke (BAY 19767)	Dr Malozzi, C	Bayer Us LLC	16,257.00
	63949	NN7533-4470- ASCENT A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine-Tetrahydrouridine (NDec) in Patients with Sickle Cell Disease (NN7533-4470 - ASCENT)	Dr Hogue, A	Novo Nordisk	2,800.00
				Total Internal Medicine	**58,987.00**
Mitchell Cancer Institute					
	63799	PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer	Dr Prodduturbar, P	Alliance Foundation	2,100.00
	63937	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess theEfficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for thePrevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients ReceivingModerately Emetogenic Chemotherapy (LP-CT-PALO 202101)	Dr Butler, T	Xiamen LP Pharmaceuticals	9,650.51
	63938	BO44178- A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study Of RO7247669 Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy In Patients With Previously Untreated Locally Advanced Or Metastatic Non Small Cell Lung Cancer (Roche - BO44178)	Dr Prodduturbar, P	Roche - Genentech, Inc.	16,200.00

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over $2,000)
October 1, 2023 - September 30, 2024

Department	Project Number	Project Title	Principal Investigator	Source of Funding	23-24 Receipts
	63946	A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) (LOXO-BTX-20022)	Dr Alkharabsheh, O	Loxo Oncology, Inc.	15,210.00
	63953	A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia (BeiGene - BGB-3111-402)	Dr Alkharabsheh, O	BeiGene, Ltd.	10,200.00
	63955	A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE - D4191C00140)	Dr Abdalla, A	AstraZeneca Pharmaceuticals LP	34,202.80
	63957	A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi 304) (AMG 757-20210004)	Dr Prodduturbar, P	Amgen, Inc.	14,700.00
	63960	A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011-0014)	Dr Alkharabsheh, O	Merck Sharp & Dohme LLC	10,500.00
				Total Mitchell Cancer Institute	**112,763.31**

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over $2,000)
October 1, 2023 - September 30, 2024

Department	Project Number	Project Title	Principal Investigator	Source of Funding	23-24 Receipts
Neurology					
	63867	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (Xenon XPF-008-201)	Dr Naritoku, D	Xenon Pharaceuticals, Inc.	3,966.06
	63940	A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (Xenon XPF-010-301)	Dr Naritoku, D	Xenon Pharaceuticals, Inc.	15,400.00
`	63941	A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (Xenon XPF-010-303)	Dr Naritoku, D	Xenon Pharaceuticals, Inc.	9,450.00
				Total Neurology	**28,816.06**

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over $2,000)
October 1, 2023 - September 30, 2024

Department	Project Number	Project Title	Principal Investigator	Source of Funding	23-24 Receipts
Neurosurgery					
	63952	PAULA - Pelvic fixation and fusion during multilevel spinal surgery (SI-BONE - PAULA)	Dr Menger, R	SI-BONE, Inc.	26,857.50
				Total Neurosurgery	**26,857.50**
OB-GYN					
	63887	A Phase 3, Randomized, Double- or Observer-Blinded, Placebo-Controlled Trial to EvaluateThe Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Perfusion FSubunit Vacine in Infants Born to Women Vaccinated During Pregnancy Investigational (Pfizer C3671008)	Dr Roth, T	Pfizer	2,329.27
				Total OB-GYN	**2,329.27**
Pediatrics					
	63869	Bayer Healthcare Pharmaceuticals, Inc. / "HEM-POWR: Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A" (Bayer HEM-POWR)	Dr Marri, P	Bayer	2,860.00
	63913	An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial (GBT2104-133)	Dr Marri, P	Global Blood Therapeutics, Inc.	8,560.60
	63926	A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease (TAK-390MR_204)	Dr Gremse, D	Takeda Development Ctr Americas, Inc.	23,728.00

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over $2,000)
October 1, 2023 - September 30, 2024

Department	Project Number	Project Title	Principal Investigator	Source of Funding	23-24 Receipts
	63927	A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE (TAK-390MR_205)	Dr Gremse, D	Takeda Development Ctr Americas, Inc.	33,399.00
	63931	Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels (QOL - SSDXP-13)	Dr Gremse, D	QOL Medical, LLC	23,702.60
	63932	A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years (FIPCUS CLENPIQ 000359)	Dr Gremse, D	Ferring Pharmaceuticals	46,127.00
	63951	A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Children Aged >= 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease (VPED-103)	Dr Gremse, D	Phathom Pharmaceuticals, Inc.	14,200.00
				Total Pediatrics	**152,577.20**
Sickle Cell					
	63945	GBT 440-4R2 An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor) (GBT-440-4R2)	Dr Pack-Mabien, A	Global Blood Therapeutics, Inc.	54,659.70
				Total Sickle Cell	**54,659.70**

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over $2,000)
October 1, 2023 - September 30, 2024

Department	Project Number	Project Title	Principal Investigator	Source of Funding	23-24 Receipts
Surgery					
	63879	Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (MediWound MW2018-06-21)	Dr Bright, A	Mediwound	48,703.26
	63910	Research to further inform thinking about the role of LINX for Reflux Disease (Torax Rethink Reflux Registry - TRX_2018_01)	Dr Richards, W	Torax Medical/Ethicon Endo-Surgery	9,355.00
	63930	A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4 Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex®]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleeding (BE1116_3006)	Dr Butts, C	CSL Behring LLC	178,974.87
	63961	Randomized Study of the pdSTIM™ System (phrenic nerve to diaphragm STIMulation) in Failure to Wean Mechanically Ventilated Patients (ReInvigorate Study - CIP0002)	Dr Mbaka, M	Stimdia Medical, Inc.	13,460.00
				Total Surgery	**250,493.13**
Urology					
	63944	111-5702 A Real World Study of eCoin® for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE 111-5702)	Dr Blanchard-Burch, K	Valencia Technologies	10,585.00
				Total Urology	**10,585.00**
				Total All Departments	**698,068.17**

Other Research Related Revenue

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over $2,000)
October 1, 2023 - September 30, 2024

Department	Project Number	Project Title	Principal Investigator	Source of Funding	23-24 Receipts
	62648	Royalty On Sales of Antibody Products	Dr Scammell, J	Genovis / QED Bioscience	2,261.00
				Total Other Research	**2,261.00**
				Total	**700,329.17**